PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Cognika Corporation

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Cognika Announces General Availability of Trial XL™ Version 2.1 - Trial XL™, a web based solution for accelerating clinical trial operations of Pharmaceutical, Medical Devices and Biotech industry, launched as generally available
Cognika Announces General Availability of Trial XL™ Version 2.1

 

NewswireToday - /newswire/ - Brookline, MA, United States, 2010/04/05 - Trial XL™, a web based solution for accelerating clinical trial operations of Pharmaceutical, Medical Devices and Biotech industry, launched as generally available.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Cognika Corporation announced the release of Trial XL™ version 2.1, a web-based decision support tool that helps users design clinical trials and improve efficiency of clinical operations. Built on Cognika’s ESP (Extraction, Simulation and Prediction) technology, Trial XL™ reveals novel insights extracted from an exhaustive analysis of all relevant historical trials. Trial XL™ Standard Edition integrates information from numerous public data sources and delivers retrospective analyses most relevant to the clinical trial. Trial XL™ Enterprise Edition integrates in-house historical clinical trial data and other proprietary data sources to provide additional meta-analysis resulting in improved likelihood of success of the clinical program.

Starting with initial protocol assumptions like therapeutic area or medical intervention, Trial XL™ uses its ESP technology platform to:
• Find relevant conditions, interventions. primary and secondary outcomes as well as inclusion and exclusion criteria associated with similar trials;
• Define and find intent to treat population based on historical information;
• Create ready to use relevant trials table and other analytics to justify operational decisions related to choice of Sites and Principal Investigators;
• Enable users to easily select or add other relevant attributes;
• Generate quantitative insights about patient enrollment rates, compliance and accrual.

Trial XL™ includes enhanced features like:
• Contextual Virtual Profiles created on-the-fly for every answer provided, including Sites and Relevant People;
• Hyperlinks to source articles of listing for complete justification of recommendations derived using the tool and;
• Easy import and export of information for offline analysis and report creation.

Using Trial XL™ to learn from past experiences will improve the likelihood of success, operational efficiency by identifying the parameters influencing its outcome.
The immediate benefit of using Trial XL™ is to reduce the time to create a clinical trial protocol by starting with a comprehensive analysis of available public data. In the long run it will reduce the cost of clinical trials by selecting the most efficient sites and the best experts for each trial. Pharmaceutical and Biotech companies also stand to benefit significantly by being able to reduce their overall clinical development cycle and bringing drugs to market earlier.
“After proving the strength of our ESP platform in analytics of proprietary data for Pharmaceutical companies for over four years, we are very excited to launch our first commercial solution as a ready to go web based product that provides valuable answers to users from day one.” said Ram Srivastav, CEO and co-founder of Cognika.

Amit Phansalkar, VP Products added, “The critical challenge in designing and conducting a clinical trial is to rely on services or manually search vast number of documents to reach decisions surrounding time and cost estimates for the clinical trial. I am highly thrilled to present this highly effective alternative to anyone involved with designing or operationally planning the clinical trial. The results and insights provided by Trial XL are based on knowledge gleaned from millions of journal articles; hundred thousand clinical trials, US and international, information, thousands of grants, and multiple other web sources. Trial XL effectively connects the dots in the information gathered thus providing the user critical insights that can restrict the delays in clinical trial. Trial XL gives every user the access to all this information making it an unmatched tool in the industry.”

Trial XL™ is generally available now. For more information please contact info[.]cognika.com. To request evaluation access please register at trialxl.com/.

About Cognika
Cognika Corporation (cognika.com) was founded with a mission to bring leading edge analytics tools developed at MIT to market. This breakthrough technology combines the best of Artificial Intelligence (AI) techniques with unique algorithms that emulate human cognition, and serves as the foundation for the Smart Analytics engine on which Cognika ESP™ is based. Cognika Corporation has expanded its technology to fully accommodate structured and unstructured data sources, including images and video. The company's current work includes novel solutions for automated analysis, design and optimization solutions, business intelligence, knowledge management, and anticipatory search for leading organizations in information-intensive industries such as life sciences, healthcare, process industry, defense, homeland security, telecommunications, and the financial sector.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Cognika Corporation

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Cognika Announces General Availability of Trial XL™ Version 2.1

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Cognika | Trial XL
Publisher Contact: Marketing Manager - Cognika.com 
617-794-6237 info[.]cognika.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Cognika Corporation securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Cognika Corporation / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)